Post by BioM Biotech Cluster Development GmbH

Wow! 🚀 EUR 910 Million Raised – Record Year for Bavarian Biotech in 2024 More than EUR 910 million in private and public #financing have been risen by #biotech companies in #Bavaria in 2024 – a substantial increase that nearly doubled the EUR 470 million secured in 2023. This sharp increase reflects growing #investor confidence in Bavaria's life sciences sector. Notably, over 60% of the total funding volume was concentrated in just four companies – a clear signal of strong scalability and momentum among key players of the Bavarian biotech ecosystem: 🔹 ITM Isotope Technologies Munich SE (Radiopharmaceuticals) 🔹 CatalYm GmbH (Immuno-oncology) 🔹 Tubulis GmbH (Antibody-Drug Conjugates) 🔹 SciRhom GmbH (Autoimmune Therapeutics) Learn how these companies plan to leverage their new capital – and what this means for patients and the Bavarian biotech ecosystem – in our latest #BioM #BiotechReport 👉 "BIOTECH IN BAVARIA - ONE WORLD FOR INNOVATION": https://lnkd.in/eaZZTPJb A cordial “Thank you” the contributors to this article: Dr. Klaus Maleck, CFO, #ITM Isotope Technologies Munich SE, Anne Burger, CFO, #CatalYm GmbH, Dr. Dominik Schumacher, CEO and co-founder and Dr. Jonas Helma-Smets, CSO and co-founder, #Tubulis GmbH, and Dr. Jan Poth, CEO, #SciRhom GmbH. #BavarianBiotechReport #InnovationinBavaria #BavarianBiotechnologyCluster #Investment #BioM #Innovation #Growth #Startups #ADC #Radiopharma